# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,DIQMTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
abrilumab,DIQMTQSPSSVSASVGDRVTITCRASLAWYQQKPGKAPKLLIYNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCFGQGTKVEIK,0.0,0,jain2017_pnas
adalimumab,DIQMTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
alemtuzumab,DIQMTQSPSSLSASVGDRVTITCKASLNWYQQKPGKAPKLLIYNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
alirocumab,DIVMTQSPDSLAVSLGERATINCKSSLGWYQQKPGQPPNLLIYTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFGQGTKLEIK,0.0,0,jain2017_pnas
anifrolumab,EIVLTQSPGTLSLSPGERATLSCRASFAWYQQKPGQAPRLLIYSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCFGQGTRLEIK,0.0,0,jain2017_pnas
atezolizumab,DIQMTQSPSSLSASVGDRVTITCRASVAWYQQKPGKAPKLLIYFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
bapineuzumab,DVVMTQSPLSLPVTPGEPASISCKSSLNWLLQKPGQSPQRLIYKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
basiliximab,QIVSTQSPAIMSASPGEKVTMTCSASMQWYQQKPGTSPKRWIYKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCFGGGTKLEIK,0.0,0,jain2017_pnas
bavituximab,DIQMTQSPSSLSASLGERVSLTCRASLNWLQQGPDGTIKRLIYSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCFGAGTKLELK,0.0,0,jain2017_pnas
belimumab,SSELTQDPAVSVALGQTVRVTCQGDASWYQQKPGQAPVLVIYNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCFGGGTELTVL,1.0,6,jain2017_pnas
benralizumab,DIQMTQSPSSLSASVGDRVTITCGTSLNWYQQKPGKAPKLLIYRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
bevacizumab,DIQMTQSPSSLSASVGDRVTITCSASLNWYQQKPGKAPKVLIYSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
bimagrumab,QSALTQPASVSGSPGQSITISCTGTVNWYQQHPGKAPKLMIYKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCFGGGTKLTVL,0.0,0,jain2017_pnas
blosozumab,DIQMTQSPSSLSASVGDRVTITCKASVAWYQQKPGKAPKLLIYTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,1.0,6,jain2017_pnas
bococizumab,DIQMTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGQGTKLEIK,1.0,6,jain2017_pnas
brentuximab,DIVLTQSPASLAVSLGQRATISCKASMNWYQQKPGQPPKVLIYNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCFGGGTKLEIK,,3,jain2017_pnas
briakinumab,QSVLTQPPSVSGAPGQRVTISCSGSVKWYQQLPGTAPKLLIYQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCFGTGTKVTVL,1.0,4,jain2017_pnas
brodalumab,EIVMTQSPATLSVSPGERATLSCRASLAWFQQKPGQAPRPLIYTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCFGGGTKVEIK,,1,jain2017_pnas
canakinumab,EIVLTQSPDFQSVTPKEKVTITCRASLHWYQQKPDQSPKLLIKQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCFGPGTKVDIK,0.0,0,jain2017_pnas
carlumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKVEIK,1.0,4,jain2017_pnas
certolizumab,DIQMTQSPSSLSASVGDRVTITCKASVAWYQQKPGKAPKALIYFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
cetuximab,DILLTQSPVILSVSPGERVSFSCRASIHWYQQRTNGSPRLLIKESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCFGAGTKLELK,0.0,0,jain2017_pnas
cixutumumab,SSELTQDPAVSVALGQTVRITCQGDATWYQQKPGQAPILVIYKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCFGGGTKLTVL,1.0,6,jain2017_pnas
clazakizumab,AIQMTQSPSSLSASVGDRVTITCQASLSWYQQKPGKAPKLLIYTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCFGGGTKVEIK,0.0,0,jain2017_pnas
codrituzumab,DVVMTQSPLSLPVTPGEPASISCRSSLHWYLQKPGQSPQLLIYNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKLEIK,1.0,6,jain2017_pnas
crenezumab,DIVMTQSPLSLPVTPGEPASISCRSSLHWYLQKPGQSPQLLIYNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
dacetuzumab,DIQMTQSPSSLSASVGDRVTITCRSSLHWYQQKPGKAPKLLIYNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCFGQGTKVEIK,0.0,0,jain2017_pnas
daclizumab,DIQMTQSPSTLSASVGDRVTITCSASMHWYQQKPGKAPKLLIYNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCFGQGTKVEVK,,1,jain2017_pnas
dalotuzumab,DIVMTQSPLSLPVTPGEPASISCRSSLQWYLQKPGQSPQLLIYNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,1.0,5,jain2017_pnas
daratumumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
denosumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCFGQGTKVEIK,1.0,5,jain2017_pnas
dinutuximab,EIVMTQSPATLSVSPGERATLSCRSSLHWYLQKPGQSPKLLIHNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFGAGTKLELK,0.0,0,jain2017_pnas
drozitumab,SELTQDPAVSVALGQTVRITCSGDASWYQQKPGQAPVLVIYNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCFGGGTKLTVL,0.0,0,jain2017_pnas
duligotuzumab,DIQMTQSPSSLSASVGDRVTITCRASVAWYQQKPGKAPKLLIYFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,1.0,6,jain2017_pnas
dupilumab,DIVMTQSPLSLPVTPGEPASISCRSSLDWYLQKSGQSPQLLIYNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCFGQGTKLEIK,1.0,5,jain2017_pnas
eculizumab,DIQMTQSPSSLSASVGDRVTITCGASLNWYQQKPGKAPKLLIYNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
efalizumab,DIQMTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
eldelumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGPGTKVDIK,0.0,0,jain2017_pnas
elotuzumab,DIQMTQSPSSLSASVGDRVTITCKASVAWYQQKPGKVPKLLIYTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
emibetuzumab,DIQMTQSPSSLSASVGDRVTITCSVSLHWYQQKPGKAPKLLIYNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,1.0,6,jain2017_pnas
enokizumab,DIQMTQSPSSLSASVGDRVTITCKASVTWYQQKPGKAPKLLIYYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,0.0,0,jain2017_pnas
epratuzumab,DIQLTQSPSSLSASVGDRVTMSCKSSLAWYQQKPGKAPKLLIYTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGGGTKLEIK,,1,jain2017_pnas
etrolizumab,DIQMTQSPSSLSASVGDRVTITCRASLHWYQQKPGKAPKLLIKQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,,2,jain2017_pnas
evolocumab,ESALTQPASVSGSPGQSITISCTGTVSWYQQHPGKAPKLMIYNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCFGGGTKLTVL,,2,jain2017_pnas
farletuzumab,DIQLTQSPSSLSASVGDRVTITCSVSLHWYQQKPGKAPKPWIYNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
fasinumab,DIQMTQSPSSLSASAGDRVTITCRASLGWYQQKPGKAPKRLIYNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCFGQGTKVEIK,0.0,0,jain2017_pnas
fezakinumab,QAVLTQPPSVSGAPGQRVTISCTGSVHWYQQLPGTAPKLLIYNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCFGGGTQLTVL,0.0,0,jain2017_pnas
ficlatuzumab,DIVMTQSPDSLAMSLGERVTLNCKASVSWYQQKPGQSPKLLIYNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCFGQGTKLEIK,0.0,0,jain2017_pnas
figitumumab,DIQMTQFPSSLSASVGDRVTITCRASLGWYQQKPGKAPKRLIYRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCFGQGTKLEIK,,3,jain2017_pnas
fletikumab,AIQLTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,0.0,0,jain2017_pnas
foralumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGGGTKVEIK,,2,jain2017_pnas
fresolimumab,ETVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTRLEIK,0.0,0,jain2017_pnas
fulranumab,AIQLTQSPSSLSASVGDRVTITCRASLAWYQQKPGKAPKLLIYSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,,1,jain2017_pnas
galiximab,ESALTQPPSVSGAPGQKVTISCTGSLHWYQQLPGTAPKLLIYKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCFGGGTRLTVL,0.0,0,jain2017_pnas
ganitumab,DVVMTQSPLSLPVTPGEPASISCRSSLDWYLQKPGQSPQLLIYNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
gantenerumab,DIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCFGQGTKVEIK,1.0,6,jain2017_pnas
gemtuzumab,DIQLTQSPSTLSASVGDRVTITCRASLTWFQQKPGKAPKLLMYNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFGQGTKVEVK,0.0,0,jain2017_pnas
gevokizumab,DIQMTQSTSSLSASVGDRVTITCRASLSWYQQKPGKAVKLLIYKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCFGQGTKLEIK,0.0,0,jain2017_pnas
girentuximab,DIVMTQSQRFMSTTVGDRVSITCKASVAWYQQKPGQSPKLLIYNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCFGGGTKLEIK,0.0,0,jain2017_pnas
glembatumumab,EIVMTQSPATLSVSPGERATLSCRASLVWYQQKPGQAPRLLIYTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
golimumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGPGTKVDIK,,1,jain2017_pnas
guselkumab,QSVLTQPPSVSGAPGQRVTISCTGSVHWYQQLPGTAPKLLIYKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCFGGGTKLTVL,,1,jain2017_pnas
ibalizumab,DIVMTQSPDSLAVSLGERVTMNCKSSLAWYQQKPGQSPKLLIYTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCFGGGTKLEIK,0.0,0,jain2017_pnas
imgatuzumab,DIQMTQSPSSLSASVGDRVTITCRASLNWYQQKPGKAPKRLIYNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCFGQGTKLEIK,1.0,5,jain2017_pnas
infliximab,DILLTQSPAILSVSPGERVSFSCRASIHWYQQRTNGSPRLLIKESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCFGSGTNLEVK,0.0,0,jain2017_pnas
inotuzumab,DVQVTQSPSSLSASVGDRVTITCRSSLSWYLHKPGKAPQLLIYNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,,3,jain2017_pnas
ipilimumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
ixekizumab,DIVMTQTPLSLSVTPGQPASISCRSSLHWYLQKPGQSPQLLIYNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKLEIK,1.0,6,jain2017_pnas
lampalizumab,DIQVTQSPSSLSASVGDRVTITCITSMNWYQQKPGKVPKLLISTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
lebrikizumab,DIVMTQSPDSLSVSLGERATINCRASMHWYQQKPGQPPKLLIYNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFGGGTKVEIK,0.0,0,jain2017_pnas
lenzilumab,EIVLTQSPATLSVSPGERATLSCRASVAWYQQKPGQAPRVLIYSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGGGTKVEIK,1.0,6,jain2017_pnas
lintuzumab,DIQMTQSPSSLSASVGDRVTITCRASMNWFQQKPGKAPKLLIYNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
lirilumab,EIVLTQSPVTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKLEIK,0.0,0,jain2017_pnas
lumiliximab,DIQMTQSPSSLSASVGDRVTITCRASLNWYQQKPGKAPKLLIYSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
matuzumab,DIQMTQSPSSLSASVGDRVTITCSASMYWYQQKPGKAPKLLIYNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
mavrilimumab,QSVLTQPPSVSGAPGQRVTISCTGSVSWYQQLPGTAPKLLIYKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCFGGGTKLTVL,0.0,0,jain2017_pnas
mepolizumab,DIVMTQSPDSLAVSLGERATINCKSSLAWYQQKPGQPPKLLIYTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFGGGTKLEIK,0.0,0,jain2017_pnas
mogamulizumab,DVLMTQSPLSLPVTPGEPASISCRSSLEWYLQKPGQSPQLLIYNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
motavizumab,DIQMTQSPSTLSASVGDRVTITCSASMHWYQQKPGKAPKLLIYKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFGGGTKVEIK,,1,jain2017_pnas
muromonab,QIVLTQSPAIMSASPGEKVTMTCSASMNWYQQKSGTSPKRWIYKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCFGSGTKLEIK,0.0,0,jain2017_pnas
natalizumab,DIQMTQSPSSLSASVGDRVTITCKTSMAWYQQTPGKAPRLLIHALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
necitumumab,EIVMTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGGGTKAEIK,0.0,0,jain2017_pnas
nimotuzumab,DIQMTQSPSSLSASVGDRVTITCRSSLDWYQQTPGKAPKLLIYNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGQGTKLQIT,0.0,0,jain2017_pnas
nivolumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
obinutuzumab,DIVMTQTPLSLPVTPGEPASISCRSSLYWYLQKPGQSPQLLIYNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGGGTKVEIK,0.0,0,jain2017_pnas
ocrelizumab,DIQMTQSPSSLSASVGDRVTITCRASMHWYQQKPGKAPKPLIYNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
ofatumumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTRLEIK,0.0,0,jain2017_pnas
olaratumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
olokizumab,DIQMTQSPSSLSASVGDRVTITCQASLSWYQQKPGKAPKLLIYNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKLEIK,0.0,0,jain2017_pnas
omalizumab,DIQLTQSPSSLSASVGDRVTITCRASMNWYQQKPGKAPKLLIYYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
onartuzumab,DIQMTQSPSSLSASVGDRVTITCKSSLAWYQQKPGKAPKLLIYTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
otelixizumab,DIQLTQPNSVSTSLGSTVKLSCTLSVHWYQLYEGRSPTTMIYKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCFGGGTKLTVL,0.0,0,jain2017_pnas
otlertuzumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
ozanezumab,DIVMTQSPLSNPVTLGQPVSISCRSSLNWFLQRPGQSPQLLIYTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCFGQGTKLEIK,,3,jain2017_pnas
palivizumab,DIQMTQSPSTLSASVGDRVTITCKCQMHWYQQKPGKAPKLLIYKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFGGGTKLEIK,0.0,0,jain2017_pnas
panitumumab,DIQMTQSPSSLSASVGDRVTITCQASLNWYQQKPGKAPKLLIYNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCFGGGTKVEIK,0.0,0,jain2017_pnas
panobacumab,DVVMTQSPLSLPVTLGQPASISCRSSLNWFQQRPGQSPRRLIYNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGGGTKVEIK,0.0,0,jain2017_pnas
parsatuzumab,DIQMTQSPSSLSASVGDRVTITCRTSLHWYQQKPGKAPKLLIYNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,1.0,6,jain2017_pnas
patritumab,DIEMTQSPDSLAVSLGERATINCRSSLAWYQQNPGQPPKLLIYTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFGQGTKVEIK,1.0,4,jain2017_pnas
pembrolizumab,EIVLTQSPATLSLSPGERATLSCRASLHWYQQKPGQAPRLLIYYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGGGTKVEIK,0.0,0,jain2017_pnas
pertuzumab,DIQMTQSPSSLSASVGDRVTITCKASVAWYQQKPGKAPKLLIYYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
pinatuzumab,DIQMTQSPSSLSASVGDRVTITCRSSLEWYQQKPGKAPKLLIYNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
polatuzumab,DIQLTQSPSSLSASVGDRVTITCKASLNWYQQKPGKAPKLLIYNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
ponezumab,DVVMTQSPLSLPVTLGQPASISCKSSLNWFQQRPGQSPRRLIYRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTRLEIK,1.0,4,jain2017_pnas
radretumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
ramucirumab,DIQMTQSPSSVSASIGDRVTITCRASLGWYQQKPGKAPKLLIYNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCFGGGTKVDIK,0.0,0,jain2017_pnas
ranibizumab,DIQLTQSPSSLSASVGDRVTITCSASLNWYQQKPGKAPKVLIYSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,,1,jain2017_pnas
reslizumab,DIQMTQSPSSLSASVGDRVTITCLASLAWYQQKPGKAPKLLIYSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCFGQGTKVEVK,0.0,0,jain2017_pnas
rilotumumab,EIVMTQSPATLSVSPGERATLSCRASLAWYRQKPGQAPRLLIYTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCFGQGTRLEIK,0.0,0,jain2017_pnas
rituximab,QIVLSQSPAILSASPGEKVTMTCRASIHWFQQKPGSSPKPWIYNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCFGGGTKLEIK,0.0,0,jain2017_pnas
robatumumab,EIVLTQSPGTLSVSPGERATLSCRASLHWYQQKPGQAPRLLIKQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTKVEIK,1.0,4,jain2017_pnas
romosozumab,DIQMTQSPSSLSASVGDRVTITCRASLNWYQQKPGKAPKLLIYRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,0.0,0,jain2017_pnas
sarilumab,DIQMTQSPSSVSASVGDRVTITCRASLAWYQQKPGKAPKLLIYSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCFGQGTKLEIK,0.0,0,jain2017_pnas
secukinumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTRLEIK,0.0,0,jain2017_pnas
seribantumab,QSALTQPASVSGSPGQSITISCTGTVSWYQQHPGKAPKLIIYQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCFGGGTKVTVL,0.0,0,jain2017_pnas
sifalimumab,EIVLTQSPGTLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCFGQGTKVEIK,,3,jain2017_pnas
siltuximab,QIVLIQSPAIMSASPGEKVTMTCSASMYWYQQKPGSSPRLLIYNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCFGGGTKLEIK,0.0,0,jain2017_pnas
simtuzumab,DIVMTQTPLSLSVTPGQPASISCRSSLYWFLQKPGQSPQFLIYNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGGGTKVEIK,1.0,6,jain2017_pnas
sirukumab,EIVLTQSPATLSLSPGERATLSCSASMYWYQQKPGQAPRLLIYNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGGGTKVEIK,1.0,5,jain2017_pnas
tabalumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
tanezumab,DIQMTQSPSSLSASVGDRVTITCRASLNWYQQKPGKAPKLLIYRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGQGTKLEIK,,1,jain2017_pnas
teplizumab,DIQMTQSPSSLSASVGDRVTITCSASMNWYQQTPGKAPKRWIYKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCFGQGTKLQIT,,2,jain2017_pnas
tigatuzumab,DIQMTQSPSSLSASVGDRVTITCKASVAWYQQKPGKAPKLLIYTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
tildrakizumab,DIQMTQSPSSLSASVGDRVTITCRTSLAWYQQKPGKAPKLLIYTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
tocilizumab,DIQMTQSPSSLSASVGDRVTITCRASLNWYQQKPGKAPKLLIYRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
tovetumab,DIQMTQSPSSLSASVGDRVSITCRPSINWYQQKPGKAPKLLIHSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTRLEMK,0.0,0,jain2017_pnas
tralokinumab,SYVLTQPPSVSVAPGKTARITCGGNVHWYQQKPGQAPVLVIYDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCFGGGTKLTVL,0.0,0,jain2017_pnas
trastuzumab,DIQMTQSPSSLSASVGDRVTITCRASVAWYQQKPGKAPKLLIYFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCFGQGTKVEIK,0.0,0,jain2017_pnas
tremelimumab,DIQMTQSPSSLSASVGDRVTITCRASLDWYQQKPGKAPKLLIYSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGPGTKVEIK,0.0,0,jain2017_pnas
urelumab,EIVLTQSPATLSLSPGERATLSCRASLAWYQQKPGQAPRLLIYNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFGGGTKVEIK,0.0,0,jain2017_pnas
ustekinumab,DIQMTQSPSSLSASVGDRVTITCRASLAWYQQKPEKAPKSLIYSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKLEIK,,3,jain2017_pnas
vedolizumab,DVVMTQSPLSLPVTPGEPASISCRSSLSWYLQKPGQSPQLLIYNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGQGTKVEIK,0.0,0,jain2017_pnas
veltuzumab,DIQLTQSPSSLSASVGDRVTMTCRASIHWFQQKPGKAPKPWIYNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCFGGGTKLEIK,0.0,0,jain2017_pnas
visilizumab,DIQMTQSPSSLSASVGDRVTITCSASMNWYQQKPGKAPKRLIYKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,,3,jain2017_pnas
zalutumumab,AIQLTQSPSSLSASVGDRVTITCRASLVWYQQKPGKAPKLLIYSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCFGGGTKVEIK,,1,jain2017_pnas
zanolimumab,DIQMTQSPSSVSASVGDRVTITCRASLAWYQHKPGKAPKLLIYSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFGQGTKLEIK,0.0,0,jain2017_pnas
